AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12516955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study 9660024 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic (LAP) technique
Number of subjects: 109
Study 9660024 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) technique
Number of subjects: 109
Study 7644247 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-2 (4 Hz)
Number of subjects: 32
Study 7644247 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 7644247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7644247 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-1 (110 Hz)
Number of subjects: 32
Study 2541193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg by pressurized aerosol)
Number of subjects: 8
Study 2541193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2541193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (postchallenge)
Number of subjects: 8
Study 2541193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (before challenge)
Number of subjects: 8
Study 2541193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (before challenge)
Number of subjects: 8
Study 30565022 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline added to prednisolone
Number of subjects: 301
Study 30565022 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisolone
Number of subjects: 301
Study 28270216 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (B longum BB536, B infantis M-63, B breve M-16V); 1 sachet/day for 4 weeks
Number of subjects: 40
Study 28270216 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 1 sachet/day for 4 weeks
Number of subjects: 40
Study 25401686 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Connect Online (PCO)
Number of subjects: 88
Study 25401686 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 88
Study 23486300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity programme for 25 weeks
Number of subjects: 76
Study 21483003 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m², intravenously over 4 hours, three times a day for 3 days in 6-week cycles)
Number of subjects: 233
Study 21483003 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 233
Study 21483003 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 233
Study 19037613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate)
Number of subjects: 0
Study 19037613 — intervention group
Group type: COMPARATOR
Intervention: 10 mL water (control group)
Number of subjects: 0
Study 17237314 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 (2.5, 5, 10, 20, 40, or 80 microg/d) for 30 days
Number of subjects: 67
Study 17237314 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 (5.9 microg/d)
Number of subjects: 67
Study 17237314 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12
Number of subjects: 67
Study 16356087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular preincision infiltration with 10 ml of bupivacaine (0.5%)
Number of subjects: 39
Study 16356087 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (Control Group)
Number of subjects: 39
Study 11953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive dynamic posture training program
Number of subjects: 0
Study 11953540 — intervention group
Group type: COMPARATOR
Intervention: Exercise only group
Number of subjects: 0
Study 9474608 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30
Study 9474608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral antrostomy (one-step)
Number of subjects: 30
Study 9474608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral antrostomy (two-step)
Number of subjects: 30
Study 7650933 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraversion and social support
Number of subjects: 581
Study 7650933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism and stress
Number of subjects: 581
Study 7650933 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, better education, and social support
Number of subjects: 581
Study 7650933 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, extraversion, and social support
Number of subjects: 581
Study 7650933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 581
Study 2502837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg, single oral dose)
Number of subjects: 100
Study 2502837 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (3 g) and Probenecid (1 g, single oral dose)
Number of subjects: 100
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at 20 mug/min in group I
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at 20 mug/min in group II
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion at higher doses in group III
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in all groups
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group I
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group II
Number of subjects: 27
Study 1269432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion in group III
Number of subjects: 27
Study 31770656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital and post-discharge quality improvement intervention
Number of subjects: 161
Study 31770656 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level digital intervention (optional)
Number of subjects: 161
Study 31770656 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study 30797492 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + N (necitumumab 800 mg on days 1 and 8 of a 3-week cycle, gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Number of subjects: 181
Study 30797492 — intervention group
Group type: COMPARATOR
Intervention: GC (gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Number of subjects: 181
Study 30797492 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + N
Number of subjects: 181
Study 30797492 — intervention group
Group type: COMPARATOR
Intervention: GC
Number of subjects: 181
Study 28183232 — intervention group
Group type: EXPERIMENTAL
Intervention: Triterpenoids and polysaccharide‐enriched Ganoderma lucidum (GL)
Number of subjects: 42
Study 28183232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25297337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine/verapamil (40 mg orally after converting to sinus rhythm)
Number of subjects: 92
Study 25297337 — intervention group
Group type: COMPARATOR
Intervention: Adenosine only (6 mg rapid bolus intravenous injection followed by two repeated doses of 12 mg if necessary)
Number of subjects: 92
Study 25297337 — intervention group
Group type: COMPARATOR
Intervention: Adenosine only
Number of subjects: 92
Study 25297337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine/verapamil
Number of subjects: 92
Study 22420785 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast
Number of subjects: 40
Study 22420785 — intervention group
Group type: COMPARATOR
Intervention: Web
Number of subjects: 40
Study 21883295 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy resin‐based AH Plus sealer
Number of subjects: 120
Study 21883295 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydimethylsiloxane‐based GuttaFlow sealer
Number of subjects: 120
Study 21883295 — intervention group
Group type: COMPARATOR
Intervention: Thermafil filling method
Number of subjects: 120
Study 21883295 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave filling method
Number of subjects: 120
Study 19235368 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC frame
Number of subjects: 84
Study 19235368 — intervention group
Group type: COMPARATOR
Intervention: BrainLab thermoplastic mask
Number of subjects: 84
Study 17284909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) mouth rinse
Number of subjects: 1101
Study 17284909 — intervention group
Group type: COMPARATOR
Intervention: placebo mouth rinse
Number of subjects: 1101
Study 15097956 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream, applied once daily 5 or 7 times a week for 6 weeks
Number of subjects: 0
Study 15097956 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream, applied once daily 5 or 7 times a week for 6 weeks
Number of subjects: 0
Study 11686827 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic‐citric‐acid‐ester (PLA) GTR membrane therapy
Number of subjects: 10
Study 11686827 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolide‐lactic‐copolymer (PGL) GTR membrane therapy
Number of subjects: 10
Study 11686827 — intervention group
Group type: COMPARATOR
Intervention: Healthy control sites (untreated)
Number of subjects: 10
Study 9219202 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet (HE)
Number of subjects: 14
Study 9219202 — intervention group
Group type: COMPARATOR
Intervention: No Helmet (NH)
Number of subjects: 14
Study 9219202 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-humid environment (H)
Number of subjects: 14
Study 9219202 — intervention group
Group type: COMPARATOR
Intervention: Hot-dry environment (D)
Number of subjects: 14
Study 8424291 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 60
Study 8424291 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anaesthesia with isoflurane
Number of subjects: 60
Study 3690108 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of combined individual and family psychotherapy
Number of subjects: 30
Study 3690108 — intervention group
Group type: COMPARATOR
Intervention: 12 sessions of dietary advice
Number of subjects: 30
Study 29793565 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal thermo-sensitive gel (TLTG)
Number of subjects: 81
Study 29793565 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 81
Study 25795459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative occupational therapy intervention (home visit by an occupational therapist)
Number of subjects: 44
Study 25795459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 44
Study 25795459 — intervention group
Group type: EXPERIMENTAL
Intervention: Health related quality of life and resource use assessments
Number of subjects: 44
Study 26300269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment with long-acting somatostatin analogue (SSA)
Number of subjects: 0
Study 26300269 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 0
Study 26300269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative SSA treatment
Number of subjects: 0
Study 26300269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pegvisomant treatment
Number of subjects: 0
Study 23609368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (200 µg)
Number of subjects: 56
Study 23609368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intrathecal morphine)
Number of subjects: 56
Study 20557707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 0
Study 20557707 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam (0.3 mg/kg)
Number of subjects: 0
Study 19021008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine by intravenous route before induction
Number of subjects: 60
Study 19021008 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mg/kg 0.2% ropivacaine caudally and 2ml normal saline intravenously
Number of subjects: 60
Study 19021008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg 0.2% ropivacaine caudally and 0.5mg/kg ketamine by intravenous route
Number of subjects: 60
Study 16640101 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine (3TC; 25 patients)
Number of subjects: 72
Study 16640101 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha2a (peg-IFN-alpha2a) 180 mg weekly plus 3TC (23 patients)
Number of subjects: 72
Study 16640101 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon-alpha2a 180 mg weekly plus placebo (24 patients)
Number of subjects: 72
Study 16640101 — intervention group
Group type: EXPERIMENTAL
Intervention: combination therapy (peg-IFN-alpha2a and 3TC)
Number of subjects: 72
Study 14559932 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-ingredient multivitamin supplementation
Number of subjects: 182
Study 14559932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 11050695 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion-olive-oil maceration capsule formulation
Number of subjects: 0
Study 11050695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9065544 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 52
Study 9065544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 9065544 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction test
Number of subjects: 52
Study 8351023 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 to 150 mg/d
Number of subjects: 100
Study 8351023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3717537 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine orally and scopolamine transdermally
Number of subjects: 38
Study 3717537 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine and scopolamine
Number of subjects: 38
Study 29703659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: hot pack and exercises
Number of subjects: 79
Study 29703659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: hot packs, exercises and interferential current
Number of subjects: 79
Study 29703659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: hot packs, exercises and TENS
Number of subjects: 79
Study 29703659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: hot packs, exercises and ultrasound
Number of subjects: 79
Study 27274218 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 496
Study 27274218 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 496
Study 24411556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 301
Study 22775130 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of rumination in response to unpleasant daily events
Number of subjects: 157
Study 22775130 — intervention group
Group type: COMPARATOR
Intervention: Lower use of rumination in response to unpleasant daily events
Number of subjects: 157
Study 20037494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-stream bathing
Number of subjects: 14
Study 20037494 — intervention group
Group type: COMPARATOR
Intervention: Normal bathing
Number of subjects: 14
Study 18725220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 181
Study 18725220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 181
Study 18725220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 or 15 mg)
Number of subjects: 181
Study 18725220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15910347 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sevoflurane
Number of subjects: 60
Study 15910347 — intervention group
Group type: COMPARATOR
Intervention: 8% sevoflurane
Number of subjects: 60
Study 12803505 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 20
Study 12803505 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan (CU) membrane
Number of subjects: 20
Study 9735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0
Study 9735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 9735583 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management
Number of subjects: 0
Study 9735583 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clinical management
Number of subjects: 0
Study 7604684 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiphospholipid antibodies (aPA) measured by anticardiolipin antibodies (aCL)
Number of subjects: 414
Study 7604684 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-SGA children)
Number of subjects: 414
Study 2662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 45 mg daily dose
Number of subjects: 332
Study 2662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg daily dose
Number of subjects: 332
Study 2662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 75 mg daily dose
Number of subjects: 332
Study 2662354 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 75 mg daily dose in 15-29 year old patients
Number of subjects: 332
Study 30967307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-animal protein diet (30 E% protein, 40 E% carbohydrates, 30 E% fat)
Number of subjects: 37
Study 30967307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-plant protein diet (30 E% protein, 40 E% carbohydrates, 30 E% fat)
Number of subjects: 37
Study 30967307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study 29214645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg.kg‐1
Number of subjects: 304
Study 29214645 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 40 μg.kg‐1 and glycopyrrolate 400 μg
Number of subjects: 304
Study 27922922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene and relaxation intervention (60-minute educational session, use of storybooks for deep breathing and progressive muscle relaxation)
Number of subjects: 20
Study 27922922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 20
Study 26481162 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LV thrombi detected by cardiac magnetic resonance
Number of subjects: 738
Study 26481162 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LV thrombi
Number of subjects: 738
Study 23313840 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle knife sphincterotomy (NKS)
Number of subjects: 73
Study 23313840 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation
Number of subjects: 73
Study 23313840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 20800380 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 25 Gy in 10 daily fractions (Arm 1)
Number of subjects: 265
Study 20800380 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy (Arm 2 and Arm 3)
Number of subjects: 265
Study 20800380 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with daily 18 fractions (Arm 2)
Number of subjects: 265
Study 20800380 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with twice-daily 24 fractions (Arm 3)
Number of subjects: 265
Study 19245692 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for patients (6-month intervention with 20 group sessions and 12 monthly phone contacts)
Number of subjects: 574
Study 19245692 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement-type intervention for physicians (training and performance monitoring)
Number of subjects: 574
Study 19245692 — intervention group
Group type: COMPARATOR
Intervention: Usual care for patients (control group)
Number of subjects: 574
Study 19245692 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for patients
Number of subjects: 574
Study 19245692 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement-type intervention for physicians
Number of subjects: 574
Study 17124621 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + placebo
Number of subjects: 16
Study 17124621 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg
Number of subjects: 16
Study 17124621 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg + ketanserin (5-HT(2a) antagonist) 50 mg
Number of subjects: 16
Study 17124621 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 16
Study 15134388 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized oral NADH (10 mg/day)
Number of subjects: 26
Study 15134388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11772296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue factor pathway inhibitor (TFPI)
Number of subjects: 0
Study 11772296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 7.5 mg over 1 h followed by 10 mg/day for up to 5 days
Number of subjects: 725
Study 9619701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 9619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole (in patients with mild to moderate stroke)
Number of subjects: 725
Study 9619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 725
Study 7930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.6 micrograms/min per 100 ml tissue volume)
Number of subjects: 30
Study 7930256 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (n = 10)
Number of subjects: 30